SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Business
Alpine, Anjarium and Amolyt Net New Funds on Lucrative Investment Day
The proceeds will be used for the companies’ growth, to help develop their platforms and advance their pipelines.
September 16, 2021
 · 
3 min read
 · 
Alex Keown
Courtesy of AbbVie, Inc.
Business
AbbVie, REGENXBIO Partner on Potential One-Time Treatment for Wet AMD
The drug, called RGX-314, is a possible one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal diseases.
September 13, 2021
 · 
2 min read
 · 
Vanessa Doctor, RN
SKYRIZI is the new option for psoriatic arthritis.
Policy
FDA Crackdown on JAK Drug Class Unwelcome News for Pharma Giants
Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.
September 2, 2021
 · 
4 min read
 · 
BioSpace Editorial Staff
Courtesy of Intellia Therapeutics
Genetown
Biotech Company Driven by Cutting Edge Science and Patients, Not Ego
On June 26, Intellia announced the first-ever clinical data supporting the safety and efficacy of in vivo CRISPR genome editing in human patients.
August 30, 2021
 · 
5 min read
 · 
Heather McKenzie
Employer Resources
As Delta Variant Surges, More Biopharma Companies Mandate COVID-19 Vaccines
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
August 19, 2021
 · 
4 min read
 · 
Kate Goodwin
Courtesy of Abbvie Inc.
Deals
AbbVie’s Soliton Acquisition Hits a Snag as FTC Increases Scrutiny
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
August 11, 2021
 · 
2 min read
 · 
Mark Terry
AbbVie recently returned the rights of eye drug Ab
BioMidwest
PAbbVie Returns Eye Drug Abicipar Pegol Rights to Molecular Partners
AbbVie has terminated its license and collaboration deal with Molecular Partners for abicipar pegol, and returned all rights to the Swiss company. Here’s more about it.
August 9, 2021
 · 
3 min read
 · 
Mark Terry
Kate Krav-Rude/Shutterstock
Business
Mission and AbbVie Reach Second Milestone in Alzheimer’s, Parkinson’s Drug Research
Mission Therapeutics and AbbVie announced their DUB inhibitor collaboration back in 2018.
August 9, 2021
 · 
2 min read
 · 
Brandon May
Courtesy of Smith Collection/Gado/Getty Images
Policy
AbbVie’s Humira Sales Drop Internationally from Biosimilar Competition, but Not in the U.S.
Biosimilars have gained traction in Europe, but not in the U.S. AbbVie’s Humira is often made as an example of how companies are using legal tactics to delay biosimilar competition.
August 4, 2021
 · 
3 min read
 · 
Mark Terry
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
BioMidwest
AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress
May 24, 2022
 · 
27 min read
Drug Development
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
May 23, 2022
 · 
15 min read
Drug Development
CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis
May 23, 2022
 · 
16 min read
FDA
AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson’s Disease
May 20, 2022
 · 
9 min read
BioMidwest
AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®
May 16, 2022
 · 
19 min read
Business
AbbVie and Cugene Announce Collaboration in Autoimmune Diseases
May 16, 2022
 · 
5 min read
Job Trends
AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses
May 12, 2022
 · 
38 min read
Business
AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education
May 12, 2022
 · 
3 min read
Drug Development
Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn’s Disease
May 11, 2022
 · 
21 min read
Job Trends
AbbVie Chooses Cerebras Systems to Accelerate AI Biopharmaceutical Research
May 5, 2022
 · 
4 min read
Load More